TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year

Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025

Read more at globenewswire.com